Axcella to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Axcella Health, a biotechnology company pioneering transformative
medicines for patients with conditions where disrupted amino acid
biology plays a critical role, announced today that Robert Connelly,
President and Chief Executive Officer, will present a company overview
at the JMP Securities Life Sciences Conference in New York, N.Y. The
presentation will take place June 22, 2016, at 3 p.m. EDT.

About Axcella Health

Axcella Health is pioneering revolutionary new medicines with a focus on
amino acid homeostasis. The company has discovered more than 2,000
diseases with amino acid imbalances and developed a systems pharmacology
approach to restore health at the cellular level. Axcella’s proprietary
platform is clinically validated across several indication areas, with
clinical-stage candidates in muscle, neurodegenerative and liver
conditions. Axcella is led by a team with a strong track record of
leaving a lasting impact on the therapeutic landscape through the
development of novel products. The company was founded by VentureLabs,
the Innovation Foundry at Flagship Ventures, and has received additional
funding from Fidelity Research & Management Group, Gurnet Point Capital
and Nestlé Health Science. Axcella is based in Cambridge, Mass. For more
information, visit www.axcellahealth.com.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160615005145/en/